DLL3 and neuroendocrine neoplasm: Brcic et al. (12) investigated four different DLL3 antibodies (VenA (clone SP347; Ventana, Roche, Tucson, AZ, USA), NovA (NBP2–24669; Novus Biological, Littleton, CA, USA), TherA (PA5–26336; Thermo Fisher Scientific, Waltham, MA, USA), and AbcA (ab103102; Abcam, Cambridge, MA, USA)) for their reliability to detect DLL3 expression in high-grade neuroendocrine tumors of the lung.